Marksans Pharma (MARKSANS) Share Price Falls 5.15% to Rs 308.55
- September 30, 2026
- Posted by: Kunal Singla
- Category: News
Marksans Pharma Share Price was at Rs 308.55, down 5.15% from the previous close of Rs 325.30, with the company valued at Rs 14,698.37 crore in market capitalisation. The move placed Marksans Pharma Share Price in focus across Marksans Pharma Share Price Today searches, because the decline was clear, the range was tight and the valuation backdrop remains relevant for a Mid Cap healthcare name. Univest figures confirm the price action, but they do not point to a specific company trigger. That makes this Marksans Pharma Share Price update a case of price action first, with fundamentals and sector context needed to understand the broader setup. As of 08 October 2026 at 11:53:19 AM IST, the stock remains an active Marksans Pharma Share Price story in the healthcare space.
Marksans Pharma (MARKSANS) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 308.55 |
| Previous Close | Rs 325.3 |
| Today's Move | -Rs 16.75 (-5.15%) |
| Open | Rs 326.1 |
| High | Rs 326.25 |
| Low | Rs 307.55 |
| Market Capitalisation | Rs 14,698.37 crore |
| Market Cap Category | Mid Cap |
Marksans Pharma Share Price Today shows a decline from Rs 325.30 to Rs 308.55, a drop of Rs 16.75 or 5.15%. The stock opened at Rs 326.10, touched a high of Rs 326.25 and a low of Rs 307.55, which means the Marksans Pharma Share Price moved lower after opening near the prior level and then traded close to the day’s low. Market capitalisation stood at Rs 14,698.37 crore, and the company is classified as a Mid Cap. For Marksans Pharma Share Price observers, this pattern is important because the day’s decline was visible without any confirmed company-specific explanation. The move also keeps Marksans Pharma Stock News in focus for readers tracking Marksans Pharma Share Price Live rather than waiting for a later market close. In Univest terms, this is a straightforward price fall story, and the next lens is Marksans Pharma Fundamental Analysis.
Marksans Pharma (MARKSANS) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 14,698.37 crore |
| P/E Ratio | 28.53x |
| P/B Ratio | 4.64x |
| ROE | 15.31% |
| ROCE | 21.1% |
| EPS | Rs 11.4 |
| Book Value Per Share | Rs 70.16 |
| Dividend Yield | 0.28% |
Marksans Pharma (MARKSANS) fundamental metrics show P/E 28.53x, P/B 4.64x, ROE 15.31%, ROCE 21.1%. Taken on their own, these numbers offer context rather than a trading signal.
Marksans Pharma has a market capitalisation of Rs 14,698.37 crore and falls in the Mid Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 28.53x, P/B at 4.64x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 15.31% and ROCE of 21.1%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 11.4, book value per share of Rs 70.16, dividend yield of 0.28%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 31.87x, median ROE of 11.61%, median ROCE of 13.46%. They set out the fundamental picture and are not a rating on the stock.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 28.53x |
| Benchmark Median P/E | 31.87x |
| Benchmark Average P/E | 48.48x |
| Benchmark P/E Range | 3.58x to 708.87x |
| Company P/B Ratio | 4.64x |
| Benchmark Median P/B | 2.98x |
| Benchmark Average P/B | 4.31x |
| Company ROE | 15.31% |
| Benchmark Median ROE | 11.61% |
| Benchmark Average ROE | 10.59% |
| Company ROCE | 21.1% |
| Benchmark Median ROCE | 13.46% |
| Benchmark Average ROCE | 13.36% |
| Company Market Capitalisation | Rs 14,698.37 crore |
| Benchmark Median Market Cap | Rs 854.81 crore |
| Benchmark Average Market Cap | Rs 14,121.7 crore |
Marksans Pharma (MARKSANS) operates in the Healthcare sector, within the Pharmaceuticals & Drugs industry.
Marksans Pharma (MARKSANS) has a P/E ratio of 28.53x, which is below the benchmark median of 31.87x, a difference of -10.48%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Marksans Pharma (MARKSANS) has a ROE of 15.31%, which is above the benchmark median of 11.61%, a difference of +31.87%. Marksans Pharma (MARKSANS) has a ROCE of 21.1%, which is above the benchmark median of 13.46%, a difference of +56.76%.
Track stocks among today's decliners through the Univest top decliners screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | SUNPHARMA | 4,32,120.23 | 35.37 | 4.95 | 14.85 | 19.11 |
| Divi's Laboratories | DIVISLAB | 2,53,389.76 | 86.95 | 14.4 | 16.19 | 21.51 |
| Torrent Pharmaceuticals | TORNTPHARM | 1,81,739.76 | 82.14 | 19.96 | 26.76 | 19.27 |
| Zydus Lifesciences | ZYDUSLIFE | 1,15,710.44 | 25.51 | 4.27 | 19.69 | 21.39 |
| Laurus Labs | LAURUSLABS | 1,10,980.13 | 101.55 | 19.69 | 18.31 | 18.2 |
Marksans Pharma (MARKSANS) has a P/E ratio of 28.53x compared with the displayed peer median of 82.14x. The comparison is relative and should not be read as a recommendation. Its ROE of 15.31% compares with a peer median of 18.31% across the companies shown in the table. ROCE stood at 21.1% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. Marksans Pharma (MARKSANS) has a market capitalisation of Rs 14,698.37 crore. All 5 peers shown have a larger market capitalisation.
Why Investors Are Watching Marksans Pharma
- Marksans Pharma Share Price fell 5.15% to Rs 308.55, keeping the latest session in sharp focus.
- The stock opened near the prior level, then moved toward the day’s low, which keeps Marksans Pharma Share Price Today on watchlists.
- Marksans Pharma Fundamental Analysis shows P/E at 28.53, P/B at 4.64, ROE at 15.31% and ROCE at 21.10%.
- The company’s P/E is below the same-industry median, while its P/B is above the same-industry median.
- Marksans Pharma Stock News remains relevant because the price event is confirmed, but no company-specific catalyst is established.
About Marksans Pharma
Marksans Pharma operates in the Pharmaceuticals & Drugs industry within the Healthcare sector. Marksans Pharma Share Price is tied to a business that sits in a competitive pharmaceutical universe alongside much larger listed companies and other Mid Cap names. For readers following Marksans Pharma Share Price News, the company context matters because the stock’s valuation and return ratios need to be read against a broad healthcare peer set. The business description through the market data focuses on sector and industry positioning rather than segment detail, so the most reliable framing is that Marksans Pharma is a listed pharma company in a market where P/E, P/B, ROE and ROCE vary widely across peers. That is enough to keep Marksans Pharma Share Price analysis grounded in verified facts.
Track Marksans Pharma Share Price on Univest
Use Marksans Pharma (MARKSANS) live share-price page, Univest top decliners screener, Univest market blogs to review live stock data, top decliners and related market analysis.
If you want to follow Marksans Pharma Share Price Live, Univest brings together price action, fundamental ratios, 52-week levels and market insights in one place. Marksans Pharma Share Price Today can be monitored alongside valuation ratios, market capitalisation and sector benchmarks so the move can be read in context. For Marksans Pharma Stock News, Univest also keeps the latest market update easy to track without mixing opinion with verified figures.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).
Frequently Asked Questions
Why did Marksans Pharma Share Price fall today?
Ans. Marksans Pharma Share Price fell 5.15% to Rs 308.55, but no company-specific catalyst is established in the verified data. The move is therefore best read as confirmed price action with no declared trigger attached.
What is Marksans Pharma Share Price today?
Ans. Marksans Pharma Share Price today was Rs 308.55, compared with the previous close of Rs 325.30. That places the stock lower by Rs 16.75 in the latest session and keeps the decline clearly visible.
How much did Marksans Pharma Share Price decline?
Ans. Marksans Pharma Share Price declined by 5.15%, or Rs 16.75, from Rs 325.30 to Rs 308.55. The stock opened at Rs 326.10 and touched a low of Rs 307.55 during the move.
Is Marksans Pharma a Mid Cap stock?
Ans. Yes, Marksans Pharma Share Price is being discussed here in the Mid Cap category, with market capitalisation at Rs 14,698.37 crore. That size context helps compare it with larger and smaller pharma peers.
What is Marksans Pharma Share Price valuation?
Ans. Marksans Pharma Share Price is trading at a P/E of 28.53 and a P/B of 4.64. Its P/E is below the same-industry median, while its P/B is above the same-industry median.
How strong are Marksans Pharma’s return ratios?
Ans. Marksans Pharma Share Price reflects a company with ROE of 15.31% and ROCE of 21.10%. Both figures sit above the same-industry benchmark medians, which gives the stock useful fundamental context.
What do EPS and book value show for Marksans Pharma Share Price?
Ans. EPS is Rs 11.40 and book value is Rs 70.16 per share. EPS shows earnings attributable to each share, while book value shows the accounting net worth behind each share at the current Marksans Pharma Share Price.
How does Marksans Pharma compare with pharma peers?
Ans. Marksans Pharma Share Price has a smaller market capitalisation than Sun Pharma, Divi’s Laboratories and Torrent Pharmaceuticals, but a lower P/E than several high-multiple peers. Its ROCE also compares well with many listed pharma names.
Where can investors track Marksans Pharma Share Price Live?
Ans. Investors can track Marksans Pharma Share Price Live on Univest alongside valuation ratios, market capitalisation, 52-week levels and market insights. That helps place Marksans Pharma Share Price Today in a broader research context.
